|
Published by: Business Monitor International
Published: Feb. 25, 2008 - 59 Pages
Table of Contents
- Executive Summary
- Czech Republic Pharmaceuticals And Healthcare Industry SWOT
- Czech Republic Political SWOT
- Czech Republic Economic SWOT
- Czech Republic Business Environment SWOT
- Pharmaceutical Business Environment Ratings
- Pharmaceutical Ratings - Revised Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Czech Republic - Pharmaceutical Business Environment Rat
- Table: Central And Eastern Europe Pharmaceutical Business Environment Ratings
- Limits To Potential Returns
- Risks To Realisation Of Returns
- Central And Eastern Europe Overview
- Czech Republic - Market Summary
- Regulatory Regime
- Intellectual Property Environment
- Pricing And Reimbursement Issues
- Pharmacy Sector
- Hospital Sector
- Healthcare Sector
- Research And Development Sector
- Industry Forecast Scenario
- Overall Market Forecast
- Table: Czech Republic’s Drug Market Forecast Indicators, 2005-2011
- Key Growth Factors - Industry
- Table: Czech Republic’s Health Expenditure Forecast Indicators
- Key Growth Factors - Macroeconomic
- Table: Czech Republic - Economic Activity
- Prescription And OTC Market Forecasts
- Table: Czech Republic’s Prescription Drug Market Indicators (US$mn unless otherwise stated)
- Table: OTC Drugs Market Forecast Indicators (US$mn unless otherwise stated)
- Generics And Patented Market Forecasts
- Table: Czech Republic’s Generics And Branded Market Forecast Indicators
- Export/Import Forecasts
- Table: Czech Republic Trade Indicators (US$mn)
- Other Healthcare Data Forecasts
- Table: Socio-Demographic Indicators
- Key Risks To BMI’s Forecast Scenario
- Competitive Landscape
- Wholesale
- Czech Republic Pharmaceuticals & Healthcare Report Q1 2008
- Retail
- Table: Pharmacies And Pharmacy Market Ratios
- Company Monitor
- AstraZeneca
- Bristol-Myers Squibb
- Sanofi-Aventis
- Walmark
- Zentiva (incorporating Sicomed)
- BMI Forecast Modelling
- How We Generate Our Industry Forecasts
- Pharmaceutical Industry
- Sources
AbstractThe drug market in the Czech Republic is showing promise, although local generics producers maystruggle to cash in, in the short-term. BMI forecasts a compound growth rate (CAGR) of 6.84% for 2007-2012. However, recent reforms have targeted older generic drugs, as the authorities attempts to constraincosts. Leading local producer Zentiva recorded a disappointing performance in the Czech Republic inH107, with sales receding 5.6% to CZK2,226mn (US$115.08mn), although BMI remains bullish aboutthe firms prospects in the medium to long term.
Meanwhile, after much political machination, the government has managed to push through its reformagenda, which includes a programme of tax cuts aimed at slashing the country’s large fiscal burden.Reforms include the adoption of a flat-rate system for both income and corporate tax, which willeventually stand at 15% and 19% respectively. At the same time, value-added tax (VAT) will be raised to9% from 5%. With regards to the country's welfare system, reductions in child benefits and parentalcontributions will be introduced, as well as patient fees for doctor visits and hospital stays. BMI expectshealth expenditure to reach US$19bn by 2012, or equivalent to 8% of GDP. Although low by WesternEuropean standards, it is quite high compared with its immediate neighbours. The fiscally conservativeadministration is also likely to usher in a significant shift away from state health expenditure in favour ofprivate providers.
The Czech Republic comes in second place in our revamped Business Environment Rankings. Its positionis mainly due to the strength of the drug market, with per-capita spending forecast to reach US$305.4 for2007. Patent protection, however, is a long-standing problem in the Czech Republic, due to the industrypolicy under the previous Communist government, which did not recognise patents on many end-productsand local production of copies of Western medicines. The country's EU membership and the adoption ofpharmaceutical directives have at least in theory eased many problems related to drug copying.
Get Full Details About This Report >>
|
